• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Pathology & Laboratory Medicine

UCLA Pathology & Laboratory Medicine

UCLA Pathology & Laboratory Medicine
  • About Us
    • Chair's Message
    • Leadership
    • Administration / Contacts
    • Locations
    • Licensure & Accreditation
    • Path & Lab News
    • Wellness
    • Giving to Pathology
  • Clinical Services
    • Anatomic Pathology
    • Laboratory Medicine
    • Clinical Genomics Center
    • Immunogenetics Center
    • International Collaborations
    • Olympic Lab
    • Outreach
    • Center for Telepathology and Digital Pathology
    • Quality Improvement and Clinical Innovation
  • Education
    • Pathology Grand Rounds
    • Medical & Dental Education
    • Residency Program
    • Fellowship Programs
    • Research Training
    • Allied Health Training
  • Research Enterprise
    • Infrastructure
    • Collaboration
    • Research Faculty
    • Research Training
    • Funding Opportunities
    • Research Assistants/Associates
  • Research Services
    • Brain Tumor Translational Resource (BTTR)
    • Immunogenetics (UIC)
    • Immune Assessment Core (IAC)
    • Pathology Research Portal (PRP)
    • Translational Pathology Core Laboratory (TPCL)
    • Technology Center for Genomics & Bioinformatics (TCGB)
  • Quick Links
    • Business Office
    • Faculty/Staff Resources
    • Intranet
    • Locations
    • Path IT Service Now
    • Submit Website Changes
  • Meet Our Faculty
    • Primary
    • Affiliates
    • Joint Appointment
    • MSP
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Pathology & Laboratory Medicine

Featured Articles

Featured Articles

Featured Articles

  • CICARE Team Award
  • 2014 City of Angels Fun Ride
  • Lab Gives Back Initiative
  • Medical Laboratory Professionals Week
  • Melanoma Research of Lugassy and Barnhill in Nature
  • CCFA: Role of the Microbiome in Crohn's Disease
  • Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
  • Dr. Olegario Muanantatha
  • Engage UC
  • Next Generation Sequencing Workshop with Limited Amount of RNA/DNA
  • The Educational Computer
  • Strategies to Cut the Risk of Atherosclerosis
  • Wayne Grody Pioneers DNA-based Testing
  • CICARE Team Award
  • 2014 City of Angels Fun Ride
  • Lab Gives Back Initiative
  • Medical Laboratory Professionals Week
  • Melanoma Research of Lugassy and Barnhill in Nature
  • CCFA: Role of the Microbiome in Crohn's Disease
  • Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
  • Dr. Olegario Muanantatha
  • Engage UC
  • Next Generation Sequencing Workshop with Limited Amount of RNA/DNA
  • The Educational Computer
  • Strategies to Cut the Risk of Atherosclerosis
  • Wayne Grody Pioneers DNA-based Testing
  1. Home
  2. About Us
  3. Path & Lab News
  4. Department News
  5. Strategies to Cut the Risk of Atherosclerosis

Strategies to Cut the Risk of Atherosclerosis

Peter Tontonoz, MD, PhD, is working to understand how lipids regulate cellular physiology and influence the development of metabolic disease.  His work has uncovered fundamental mechanisms involved in the control of cholesterol homeostasis and helped to define new connections between lipids, their metabolism and immune responses.  The dissection of these pathways is not only advancing the understanding of basic biological processes, but also highlighting potential opportunities for therapeutic intervention in human diseases. 

Peter Tontonoz, MD, PhDDr. Tontonoz's research has uncovered a new pathway for regulation of blood cholesterol levels that may lead to new strategies to treat heart disease.  High levels of plasma LDL cholesterol (bad cholesterol) are a strong risk factor for atherosclerosis.  A major indicator that determines the levels of LDL circulating the blood is the level of expression of the LDL receptor (LDLR).  LDLR on the plasma membrane of cells binds to circulating LDL facilitating the clearance of LDL from the blood.  Thus, higher levels of LDLR expression lead to less LDL in the blood and reduced risk of cardiovascular disease.  Statins, a well-known class of lipid lowering drugs, act by increasing LDLR expression in the liver.  Tontonoz's study of the nuclear receptor LXR, has discovered a new mechanism by which the level of cholesterol in a cell's feedback inhibits the expression of LDLR.  Identification of a protein called IDO (Inducible Degrader of the LDRL) that targets the LDLR for degradation, thereby blocking LDL uptake, may lead to the development of new drugs to lower cholesterol levels. 

Dr. Tontonoz is currently working to determine whether inhibiting IDOL activity with small molecules or molecular biological approaches may reduce LDL levels and risk for cardiovascular disease. 

Facebook Twitter Instagram Youtube LinkedIn
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap